Cargando…

Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications

BACKGROUND: Visceral adipose tissue (VAT) has a hazardous influence on systemic inflammation, insulin resistance and an adverse metabolic profile, which increases the risk of developing non-alcoholic fatty liver disease (NAFLD) and chronic complications of diabetes. In our study we aimed to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Bullón-Vela, Vanessa, Abete, Itziar, Tur, Josep A., Konieczna, Jadwiga, Romaguera, Dora, Pintó, Xavier, Corbella, Emili, Martínez-González, Miguel A., Sayón-Orea, Carmen, Toledo, Estefanía, Corella, Dolores, Macías-Gonzalez, Manuel, Tinahones, Francisco J., Fitó, Montserrat, Estruch, Ramon, Ros, Emilio, Salas-Salvadó, Jordi, Daimiel, Lidia, Mascaró, Catalina M., Zulet, Maria Angeles, Martínez, José Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586032/
https://www.ncbi.nlm.nih.gov/pubmed/33149882
http://dx.doi.org/10.1177/2042018820958298
_version_ 1783599914322755584
author Bullón-Vela, Vanessa
Abete, Itziar
Tur, Josep A.
Konieczna, Jadwiga
Romaguera, Dora
Pintó, Xavier
Corbella, Emili
Martínez-González, Miguel A.
Sayón-Orea, Carmen
Toledo, Estefanía
Corella, Dolores
Macías-Gonzalez, Manuel
Tinahones, Francisco J.
Fitó, Montserrat
Estruch, Ramon
Ros, Emilio
Salas-Salvadó, Jordi
Daimiel, Lidia
Mascaró, Catalina M.
Zulet, Maria Angeles
Martínez, José Alfredo
author_facet Bullón-Vela, Vanessa
Abete, Itziar
Tur, Josep A.
Konieczna, Jadwiga
Romaguera, Dora
Pintó, Xavier
Corbella, Emili
Martínez-González, Miguel A.
Sayón-Orea, Carmen
Toledo, Estefanía
Corella, Dolores
Macías-Gonzalez, Manuel
Tinahones, Francisco J.
Fitó, Montserrat
Estruch, Ramon
Ros, Emilio
Salas-Salvadó, Jordi
Daimiel, Lidia
Mascaró, Catalina M.
Zulet, Maria Angeles
Martínez, José Alfredo
author_sort Bullón-Vela, Vanessa
collection PubMed
description BACKGROUND: Visceral adipose tissue (VAT) has a hazardous influence on systemic inflammation, insulin resistance and an adverse metabolic profile, which increases the risk of developing non-alcoholic fatty liver disease (NAFLD) and chronic complications of diabetes. In our study we aimed to evaluate the association of VAT and the triglyceride glucose (TyG) as a proxy of insulin resistance surrogated with metabolic and liver risk factors among subjects diagnosed with metabolic syndrome (MetS). METHODS: A cross-sectional study was performed including 326 participants with MetS (55–75 years) from the PREDIMED-Plus study. Liver-status markers, VAT and TyG were assessed. Participants were stratified by tertiles according to VAT (n = 254) and TyG (n = 326). A receiver operating characteristic curve was used to analyse the efficiency of TyG for VAT. RESULTS: Subjects with greater visceral fat depots showed worse lipid profile, higher homeostatic model assessment for insulin resistance (HOMA-IR), TyG, alanine transaminase (ALT), fibroblast growth factor-21 (FGF-21), fatty liver index (FLI) and hepatic steatosis index (HSI) compared with participants in the first tertile. The multi-adjusted linear-regression analyses indicated that individuals in the third tertile of TyG (>9.1−10.7) had a positive association with HOMA-IR [β = 3.07 (95% confidence interval (CI) 2.28−3.86; p trend < 0.001)], ALT [β = 7.43 (95% CI 2.23−12.63; p trend = 0.005)], gamma glutamyl transferase (GGT) [β = 14.12 (95% CI 3.64−24.61; p trend = 0.008)], FGF-21 [β = 190.69 (95% CI 93.13−288.25; p trend < 0.001)], FLI [β = 18.65 (95% CI 14.97−22.23; p trend < 0.001)] and HSI [β = 3.46 (95% CI, 2.23−4.68; p trend < 0.001)] versus participants from the first tertile. Interestingly, the TyG showed the largest area under the receiver operating curve (AUC) for women (AUC = 0.713; 95% CI 0.62−0.79) compared with men (AUC = 0.570; 95% CI 0.48−0.66). CONCLUSIONS: A disrupted VAT enlargement and impairment of TyG are strongly associated with liver status and cardiometabolic risk factors linked with NAFLD in individuals diagnosed with MetS. Moreover, the TyG could be used as a suitable and reliable marker estimator of VAT.
format Online
Article
Text
id pubmed-7586032
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-75860322020-11-03 Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications Bullón-Vela, Vanessa Abete, Itziar Tur, Josep A. Konieczna, Jadwiga Romaguera, Dora Pintó, Xavier Corbella, Emili Martínez-González, Miguel A. Sayón-Orea, Carmen Toledo, Estefanía Corella, Dolores Macías-Gonzalez, Manuel Tinahones, Francisco J. Fitó, Montserrat Estruch, Ramon Ros, Emilio Salas-Salvadó, Jordi Daimiel, Lidia Mascaró, Catalina M. Zulet, Maria Angeles Martínez, José Alfredo Ther Adv Endocrinol Metab Cardiovascular Disease and Diabetes: Risk Factors, Prevention and Management BACKGROUND: Visceral adipose tissue (VAT) has a hazardous influence on systemic inflammation, insulin resistance and an adverse metabolic profile, which increases the risk of developing non-alcoholic fatty liver disease (NAFLD) and chronic complications of diabetes. In our study we aimed to evaluate the association of VAT and the triglyceride glucose (TyG) as a proxy of insulin resistance surrogated with metabolic and liver risk factors among subjects diagnosed with metabolic syndrome (MetS). METHODS: A cross-sectional study was performed including 326 participants with MetS (55–75 years) from the PREDIMED-Plus study. Liver-status markers, VAT and TyG were assessed. Participants were stratified by tertiles according to VAT (n = 254) and TyG (n = 326). A receiver operating characteristic curve was used to analyse the efficiency of TyG for VAT. RESULTS: Subjects with greater visceral fat depots showed worse lipid profile, higher homeostatic model assessment for insulin resistance (HOMA-IR), TyG, alanine transaminase (ALT), fibroblast growth factor-21 (FGF-21), fatty liver index (FLI) and hepatic steatosis index (HSI) compared with participants in the first tertile. The multi-adjusted linear-regression analyses indicated that individuals in the third tertile of TyG (>9.1−10.7) had a positive association with HOMA-IR [β = 3.07 (95% confidence interval (CI) 2.28−3.86; p trend < 0.001)], ALT [β = 7.43 (95% CI 2.23−12.63; p trend = 0.005)], gamma glutamyl transferase (GGT) [β = 14.12 (95% CI 3.64−24.61; p trend = 0.008)], FGF-21 [β = 190.69 (95% CI 93.13−288.25; p trend < 0.001)], FLI [β = 18.65 (95% CI 14.97−22.23; p trend < 0.001)] and HSI [β = 3.46 (95% CI, 2.23−4.68; p trend < 0.001)] versus participants from the first tertile. Interestingly, the TyG showed the largest area under the receiver operating curve (AUC) for women (AUC = 0.713; 95% CI 0.62−0.79) compared with men (AUC = 0.570; 95% CI 0.48−0.66). CONCLUSIONS: A disrupted VAT enlargement and impairment of TyG are strongly associated with liver status and cardiometabolic risk factors linked with NAFLD in individuals diagnosed with MetS. Moreover, the TyG could be used as a suitable and reliable marker estimator of VAT. SAGE Publications 2020-10-23 /pmc/articles/PMC7586032/ /pubmed/33149882 http://dx.doi.org/10.1177/2042018820958298 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Cardiovascular Disease and Diabetes: Risk Factors, Prevention and Management
Bullón-Vela, Vanessa
Abete, Itziar
Tur, Josep A.
Konieczna, Jadwiga
Romaguera, Dora
Pintó, Xavier
Corbella, Emili
Martínez-González, Miguel A.
Sayón-Orea, Carmen
Toledo, Estefanía
Corella, Dolores
Macías-Gonzalez, Manuel
Tinahones, Francisco J.
Fitó, Montserrat
Estruch, Ramon
Ros, Emilio
Salas-Salvadó, Jordi
Daimiel, Lidia
Mascaró, Catalina M.
Zulet, Maria Angeles
Martínez, José Alfredo
Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications
title Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications
title_full Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications
title_fullStr Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications
title_full_unstemmed Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications
title_short Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications
title_sort relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications
topic Cardiovascular Disease and Diabetes: Risk Factors, Prevention and Management
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586032/
https://www.ncbi.nlm.nih.gov/pubmed/33149882
http://dx.doi.org/10.1177/2042018820958298
work_keys_str_mv AT bullonvelavanessa relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT abeteitziar relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT turjosepa relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT koniecznajadwiga relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT romagueradora relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT pintoxavier relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT corbellaemili relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT martinezgonzalezmiguela relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT sayonoreacarmen relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT toledoestefania relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT corelladolores relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT maciasgonzalezmanuel relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT tinahonesfranciscoj relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT fitomontserrat relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT estruchramon relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT rosemilio relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT salassalvadojordi relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT daimiellidia relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT mascarocatalinam relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT zuletmariaangeles relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications
AT martinezjosealfredo relationshipofvisceraladiposetissuewithsurrogateinsulinresistanceandlivermarkersinindividualswithmetabolicsyndromechroniccomplications